Bio-Techne Corp (NASDAQ: TECH)’s stock price has decreased by -0.92 compared to its previous closing price of 50.0. However, the company has seen a 0.08% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-24 that MINNEAPOLIS, June 24, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide.
Is It Worth Investing in Bio-Techne Corp (NASDAQ: TECH) Right Now?
Bio-Techne Corp (NASDAQ: TECH) has a price-to-earnings ratio of 60.39x that is above its average ratio. Additionally, the 36-month beta value for TECH is 1.38. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for TECH is 154.99M and currently, short sellers hold a 4.86% ratio of that float. The average trading volume of TECH on June 25, 2025 was 2.36M shares.
TECH’s Market Performance
TECH stock saw an increase of 0.08% in the past week, with a monthly gain of 5.90% and a quarterly increase of -17.41%. The volatility ratio for the week is 1.29%, and the volatility levels for the last 30 days are 2.04% for Bio-Techne Corp (TECH). The simple moving average for the last 20 days is -0.30% for TECH stock, with a simple moving average of -23.86% for the last 200 days.
Analysts’ Opinion of TECH
Many brokerage firms have already submitted their reports for TECH stocks, with Wells Fargo repeating the rating for TECH by listing it as a “Overweight.” The predicted price for TECH in the upcoming period, according to Wells Fargo is $59 based on the research report published on May 30, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to TECH, setting the target price at $75 in the report published on March 18th of the current year.
TECH Trading at -0.10% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.76% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from Herr Amy E., who sale 1,280 shares at the price of $49.77 back on Jun 09 ’25. After this action, Herr Amy E. now owns 1,976 shares of Bio-Techne Corp, valued at $63,705 using the latest closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.66 for the gross margin
The net margin for Bio-Techne Corp stands at 0.11. The total capital return value is set at 0.08. Equity return is now at value 6.53, with 4.91 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.63. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 30.02.
Currently, EBITDA for the company is 310.37 million with net debt to EBITDA at 0.99. When we switch over and look at the enterprise to sales, we see a ratio of 6.69. The receivables turnover for the company is 5.1for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
In conclusion, Bio-Techne Corp (TECH) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
